Concord Drugs Ltd

Concord Drugs Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ending June 30, 2026. This measure, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, restricts directors, designated employees, insiders, and their immediate relatives from trading in the company's securities during this period. The specific date of the board meeting to consider these results will be communicated separately.

Concord Drugs Ltd announced its financial results for the year ending March 31, 2026. The company's revenue from operations stood at ₹7,873.68 lakhs. The Board of Directors approved the standalone and consolidated financial results in a meeting held on May 27, 2026. The profit for the period was ₹105.50 lakhs and earnings per share was ₹0.95.

Concord Drugs Ltd has announced its financial results for the quarter and year ending March 31, 2026. The Board of Directors approved the standalone and consolidated financial results during their meeting held on May 27, 2026. The results are available on the company's website and the BSE Limited website and will be published in newspapers as per SEBI regulations. Revenue from Operations increased to ₹7,873.68 lakhs in FY26 from ₹4,524.46 lakhs in FY25. Profit after tax stood at ₹105.50 lakhs in FY26 compared to ₹33.62 lakhs in FY25.

Concord Drugs Ltd's board meeting on May 27, 2026, approved the standalone and consolidated financial results for the year ended March 31, 2026. The results, along with the auditor's report, are available on the company's website and the BSE Limited website. The company's total revenue increased from ₹4,525.91 lakhs to ₹7,877.13 lakhs and profit after tax increased from ₹33.62 lakhs to ₹105.50 lakhs.

Concord Drugs Ltd's board meeting on May 27, 2026, approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results, along with the auditor's report, are available on the company's website and the BSE Limited website. The company's revenue from operations increased to ₹7,873.68 lakhs in FY26 from ₹4,524.46 lakhs in FY25. Profit after tax stood at ₹105.50 lakhs in FY26 compared to ₹33.62 lakhs in FY25.

Concord Drugs Ltd has announced that its Board of Directors will convene a meeting on May 27, 2026. The main purpose of this meeting is to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. In compliance with insider trading regulations, the trading window for the company's equity shares has been closed for all designated persons and their immediate relatives. This closure will remain in effect until 48 hours after the financial results are officially declared.

Concord Drugs Ltd has announced the closure of its trading window for the purpose of considering audited (standalone and consolidated) results for the quarter and financial year ending 31st March, 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prevention of Insider Trading. The trading window will remain closed from Wednesday, 0lst April 2026 till 48 hours after the announcement/declaration of the audited financial results. Directors, Designated Employees, Insiders, and their immediate relatives are barred from transacting securities of the company during this period. The trading window will open 48 hours after the announcement/declaration of the audited financial results for the quarter and year ending 31st March 2026.

Concord Drugs Ltd. has issued a clarification regarding an inadvertent omission in a previous disclosure related to the implementation of Labour Codes. The omission was noted in the disclosure submitted on 14th February 2026, following a Board Meeting. The company has now provided the complete paragraph regarding the implementation of the Labour Codes under the Financial Results disclosure. The New Labour Codes, which consolidate 29 existing labour legislations into four codes, have been effective from November 21, 2025. However, the corresponding supporting rules under these codes are yet to be notified. The company is continuously monitoring the finalisation of Central/State Rules and clarifications from the Government on other aspects of the New Labour Codes. The company has estimated and accounted for incremental liability for employees, which is not material to the financial results.

Concord Drugs Ltd has announced the reconstitution of certain Board Committees to ensure compliance with applicable statutory requirements. The Audit Committee and the Stakeholders’ Relationship Committee have been revised with immediate effect. The company also announced the completion of Mr. Ramchandra Reddy Kommula's tenure as an Independent Director, who has ceased to be a Director of the Company with effect from 14.02.2026. The Board has expressed gratitude for his contributions.

Concord Drugs Ltd has announced its un-audited standalone and consolidated results for the quarter ended 31st Dec, 2025. The company's Board of Directors considered and approved the financial results for the quarter and nine months ended 31st December, 2025.